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c-Jun N-terminal kinases (JNKs), also referred to as stress-activated kinases (SAPKs), were initially characterized by their activation in
response to cell stress such as UV irradiation. JNK/SAPKs have since been characterized to be involved in proliferation, apoptosis, motility,
metabolism and DNA repair. Dysregulated JNK signaling is now believed to contribute to many diseases involving neurodegeneration, chronic
inflammation, birth defects, cancer and ischemia/reperfusion injury. In this review, we present our current understanding of JNK regulation and
their involvement in homeostasis and dysregulation in human disease.
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Chronic inflammation1. Introduction
JNK/SAPKs phosphorylate c-Jun at the NH2-terminal Ser63
and 73 residues in response to UV irradiation and other stress
stimuli [1–5]. The importance of c-Jun as a member of the AP-1
transcription factors lead to an intense analysis of JNK
regulation of AP-1 function. AP-1 transcription factors are
heterodimers composed of Jun, Fos, Maf and ATF subunits [5].
c-Jun, ATF2 and ATF3 are substrates for phosphorylation by
JNKs, which enhances AP-1 transcriptional control of specific
gene expression [6].
There are three JNK genes (JNK1, JNK2, JNK3). JNK1 and
JNK2 are ubiquitously expressed while JNK3 is restricted to
brain, heart and testis [1,4,7,8]. Differential splicing and exon
usage results in multiple isoforms of the JNK1, 2 and 3 genes
[9,10]. Each JNK is expressed as a short form (46 kDa) and long
form (54 kDa) [7]. The alternative forms of each JNK1, 2 and 3⁎ Corresponding author. University of North Carolina at Chapel Hill,
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different substrate proteins [9,10]. The different JNK isoforms
can also be differentially activated [9,10]. Targeted gene disrup-
tion of each JNK has also defined differential functions for
JNK1, JNK2 and JNK3 in many different cell types involving
gene expression, apoptosis, metabolism and other critical
physiological responses [8,11–13].
1.1. JNK/SAPK Regulatory Network
As with all MAPKs, the JNKs are part of a three kinase
module. The TXY motif in the activation loop of each JNK is
dually phosphorylated by specific MAPK kinases (MKKs).
MKK4 and MKK7 phosphorylate the threonine and tyrosine
within the activation loop TXY motif (T183 and Y185 in JNK1)
resulting in JNK activation. MKKs are in turn phosphorylated at
specific serine or threonine residues within their activation loop
(S257 and T265 for MKK4; S271 and T275 for MKK7).
There are at least 20 MKKKs of which at least 14 activate
the MKK4/MKK7-JNK/MAPK pathway. Several of the
MKKKs capable of phosphorylating and activating either
MKK4 and MKK7 in the JNK pathway are also capable of
Fig. 1. Dendrogram showing the relationships between the kinase domains of
MKKKs and their ability to activate the JNK/SAPK pathway. MKKK regulation
of different MAPK pathways is accumulated from literature survey with an
emphasis on MKKK knockout data when available.
Fig. 2. (A) Organization of MKKK–MKK–MAPK interactions controlled by
docking sites, docking domains (CD, ED and docking groove), DVD site and N
lobe. See text for discussion. (B) CD (common docking) domain (bottom)
characterized by acidic residues in C-terminus of MAPK. ED site (middle) is far
from CD domain in the primary sequence, the ED site and CD domain are in the
same groove on the opposite side of catalytic center [25]. Crystal structures of
p38 and MKK3b or MEF2A define a role of another docking groove (top) in
binding to φXφmotif in docking sites [28]. Shown in red are the experimentally
proved critical residues for docking site interaction.
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activation, MKK3 and 6 for p38 activation, and MKK5 for
ERK5 activation (Fig. 1). The twenty MKKKs outnumber the
7 MKKs and 11 MAPKs. The MKKKs are differentially
regulated by protein–protein interactions and covalent mod-
ifications. Many MKKKs are activated by GTPases such as Ras
(the Raf MKKKs) or Rho family GTPases (MLK3 by Cdc42,
MEKK1 by RhoA) [14–16]. Ubiquitination may also regulate
the activity of MKKKs; including MEKK1 auto-ubiquitination
that inhibits its activity [17] or ubiquitination associated with
assembly of signaling complexes such as the IL-1 receptor
signaling complex for TAK1 [18]. Many of the MKKKs also
are phosphorylated by MKKKKs such as PAK, GCK and HPK
that may be involved in controlling MKKK activity, interaction
with other proteins and localization [19–21]. It is the diversity
of MKKK regulation resulting from differential protein–
protein interaction and covalent modifications that allow the
integration of MAPK activation in the cellular response to a
diverse range of stimuli. These stimuli include cytokines,
growth factors, antigens, cell adhesion and cell–cell interac-
tions, toxins, pharmacological drugs, and a range of stress
stimuli including heat, cold, toxicity and shear. Of the 20
defined MKKKs it is notable that at least 14 regulate the JNK
pathway, demonstrating the importance of JNK pathways in the
cellular response to external stimuli.
1.2. Organization of the JNK signaling module
JNK signaling modules are organized by two different
mechanisms: (i) recognition motifs between MKKK and MKK
and MKK and MAPKs; and (ii) Scaffold proteins that assemble
the MKKK–MKK–MAPK module in larger protein complexes
(Figs. 2 and 3).Docking interactions are achieved via conserved sequences
in the MAPKs (JNK, ERK1/2, p38, ERK5) that are selective for
the specific upstream MKK (MKK4 and 7 for JNKs) and
substrates such as c-Jun, ATF2 and others (see Table 1 for a list
of representative JNK substrates). Fig. 2 depicts the interaction
between the different motifs in MKKKs, MKK4/7 and JNKs.
On all MAPKs, including JNKs, there is a cluster of negatively
charged amino acids C-terminal to the kinase domain sequence
(Fig. 2B). This site is referred to as the common docking (CD)
domain and is used in the docking of MKKs, MAPK
phosphatases and specific substrates and scaffold proteins
Fig. 3. Function of JNK/SAPK scaffolds in organizing the MKKK–MKK4/MKK7–JNK signaling module. Known JNK scaffold proteins are listed in the box. See text
for discussion.
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Asp) domain, also contributes to the docking interactions of
MAPKs [22–26]. Docking site sequences in MKKs, substrates,
MAPK phosphatases and scaffolds share a conservedmotif of R/
K–X4–ØA–X–ØB (where ØA and ØB are the hydrophobic
residues Leu, Ile or Val) [28]. Whereas the basic residues in this
docking site bind the acidic residues of the MAPK CD domain,
the hydrophobic residues reside in a docking groove that
engages the ØA–X–ØB hydrophobic motif of the docking site.
These docking site interactions provide the specificity for
MAPK interactions and a role in the activation of the kinase [28].
In addition to the docking interactions of MAPKs with
MKKs, substrates and regulators there are specific motifs that
control the interactions of MKKKs and MKKs (Fig. 2A and B)
[29]. A docking site termed DVD (domain for versatile
docking) is found in several MKKs including MKK4/7 for
JNK regulation. The DVD site is near the extreme C-terminus
of the MKK and was shown to be involved in binding MKKKs
including MEKK1, MEKK4 (MTK1), ASK1, Tao2 and Tak1,
all of which are able to activate the JNK pathway. The N lobe
within the kinase domain of the MKKK was shown to bind to
the MKK DVD site.
An additional aspect of JNK control is the organization of
signaling complexes by scaffolding proteins (Fig. 3). Scaffold-
ing proteins generally have no catalytic function themselves,
but encode docking sites for binding members of the MAPK
module — MKKKs, MKKs and MAPKs [27]. In general,
scaffolds bind additional proteins through interaction motifs
such as SH2, SH3, PTB, and other domains that target MAPK
signaling complexes to different locations in the cell. It is often
the scaffold protein and specific MKKK that provides the
selectivity and spatio-temporal dynamics of MAPK activationby different stimuli. Fig. 3 lists known scaffold proteins for the
JNKs. Among the different scaffolds, JIPs (JNK Interacting
Proteins) bind to specific kinesins and the MLK group of
MKKKs and appear to be particularly important in cytoskeletal
tracking of the JNK module in cells such as neurons [27,30–
32]. JNK scaffolds such as arrestins are recruited to phosphory-
lated G protein-coupled receptors [33], while POSH has
multiple SH3 domains and is involved in JNK signaling in
apoptosis in mammalian cells as well as Drosophila [34–36].
Crk II scaffolds JNK signaling at focal adhesions [37]. Finally,
the MKKK, MEKK1, has been shown to bind both MKK4 and
JNK1/2, indicating it has a scaffold-like function itself, much
like PBS2 in the yeast response pathway for hyperosmotic stress
[38,39].
1.3. JNK/SAPK in disease
Roles for JNK/SAPK signaling in physiology and disease
stems mostly from the knowledge gained from biochemical
studies and mouse models where the different JNKs or
upstream regulators have been deleted by targeted homologous
recombination-gene knockouts [40]. These studies have
provided the rationale for targeting JNKs and their upstream
regulators including specific MKKKs for therapeutic interven-
tion with small molecule or peptide inhibitors [41–43]. The use
of JNK/SAPK inhibitors has further strongly supported an
important role for the JNK/SAPK pathway in several different
diseases. In particular, JNK inhibitors for the prevention of
cell death induced by ischemia and other stress-induced
apoptotic responses has shown significant therapeutic potential
[41–44]. Below the evidence for JNK/SAPK inhibitors for
therapeutic benefit in human disease is presented.
Table 1
SAPK/JNK substrates
Transcription
c-Jun
JunD
ATF2
ATF3
Elk 1
Elk-3
.p53
RXRα
RARα
Androgen receptor
NFAT4
HSF-1
c-Myc
Nuclear pore complex
Nup214
Apoptosis
Smac
Bim
Bmf
Bcl-2
Bcl-XL
Mcl-1
Microtubules
Tau
MAP1
MAP2A
DCX (doublecortin)
Amyloid β precursor protein
Signaling
IRS-1
Paxillin
14-3-3
This table represents a list of known JNK substrates. The list is not compre-
hensive but representative.
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One of the first demonstrations for the role of JNKs in
apoptosis was made with JNK3 knockout mouse [8]. JNK3 is
highly expressed in the fore- and hind- brain regions in the
mouse. JNK3 is also expressed in the heart, but unlike JNK1 and
JNK2, it is not required for embryonic development. Normally,
treatment of mice with excitotoxic agents like kainic acid causes
a marked apoptotic death of hippocampal neurons. JNK3−/−
mice are resistant to glutamate-induced excitotoxicity, clearly
demonstrating that JNK3 activation is a pro-apoptotic pathway
in hippocampal neurons. Consistent with a role for JNK3 in
excitotoxic neuronal cell death, mice expressing a mutant c-Jun
having the JNK phosphorylation sites S63 and S73 mutated to
alanines are resistant to glutamate-induced excitotoxicity. In
contrast, JNK1−/− and JNK2−/− mice are similar to wild-type
animals in their susceptibility to excitotoxic neuronal cell death
[5,44].
The role of JNK3 in excitotoxicity suggested that JNK/
SAPK pathways would be involved in other neuronal deathresponses and neurodegenerative diseases. A clear role of JNK/
SAPKs in ischemia-induced cell death has been demonstrated in
mice. Borsello et al. [45,46] used two different models of
cerebral artery occlusion: a transient occlusion in adult animals
and a permanent occlusion in 2-week-old pups. Inhibition of
JNK activity in both models protected against neuronal cell
death. A similar study in gerbils using a transient ischemia
model showed that intracerebral administration of SB203580, a
rather non-selective JNK inhibitor, reduced ischemic cell death
[47].
1.5. JNK in liver ischemia/reperfusion models
The role of JNK/SAPK pathways in ischemia-induced cell
injury goes beyond that in the CNS. Ischemia/reperfusion (I/R)
injury is a major clinical problem in several organs including
brain, heart, kidney and liver. Hepatic injury due to I/R occurs
during several conditions including transplantation, liver tumor
resection and circulatory shock. A recent study by Uehara et al.
[48] demonstrated that JNK/SAPK activity was a major
mediator of hepatic I/R injury. In this study, three ATP-
competitive, reversible and highly selective JNK inhibitors
(CC0209766, CC0223105, and CC-401 from Signal Pharma-
ceuticals, Inc.) decreased both necrosis and apoptosis of
hepatocytes and sinusoidal endothelial cells. The findings are
consistent with JNK inhibitors blocking hepatocyte apoptosis in
culture [48].
It has also been shown that the JNK inhibitor AS601245
decreases cardiomyocyte apoptosis and infarct size in a rat
cardiac I/R model in rats [49]. JNK activation in this model
occurs primarily in the reperfusion phase in response to the
generation of reactive oxygen species. Similarly, the JNK
inhibitor SP600125 was shown to improve I/R injury in the
transplantation of rat lungs [50]. In each of these models,
JNK is probably mediating the release of pro-apoptotic factors
from mitochondria, may directly phosphorylate pro-apoptotic
Bcl family members such as Bak and Bid, and induce the
expression of pro-inflammatory cytokines such as TNFα, IL-1
and IL-6.
1.6. JNK in neurodegenerative diseases
JNK3 may also prove to be a therapeutic target for
neurodegenerative diseases including Parkinson's and Alzhei-
mer's disease [44,46,51–53]. The neurotoxin 1-methyl-4-
pheny-1, 2, 4, 6- tetrahydropyridine (MPTP) induces a
neuropathology with loss of dopaminergic neurons similar to
that observed with Parkinson's disease in humans [54]. Mice
treated with MPTP have activated c-Jun, as shown by phospho-
c-Jun immunostaining. A similar activation of c-Jun is seen in
dopaminergic neurons from Parkinson's disease patients.
JNK3−/− and JNK2−/−, but not JNK1−/− mice are protected
from MPTP dopaminergic cell death. The double knockout
JNK2−/−/JNK3−/− mice have a greater dopaminergic cell
protection than either knockout alone. An important down-
stream target from JNK2 and JNK3-mediated dopaminergic cell
death was the expression of cyclooxygenase (COX) 2.
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primarily composed of β-amyloid peptide (Aβ) and neurofi-
brillary tangles composed of hyper-phosphorylated Tau protein
[55–63]. JNK3−/− are resistant to Aβ-induced apoptosis [55]. In
this model, JNK3 activates AP-1 dependent expression of Fas-
ligand [55]. There is a correlation with JNK2 and JNK3 activity
with neurofibrillary pathology including JNK phosphorylation
of Tau and the formation of Tau fibrils induced by JNK3 [64–
70]. There is some controversy as to the exact role of c-Jun
phosphorylation by JNKs versus other substrates including
Nup214, a nuclear pore complex protein, in neurodegenerative
models [71].
1.7. Hearing loss/deafness
JNK/SAPKs appear to play an important role in acquired
deafness [72]. Exposure of hair cells in the cochlea to acoustic
trauma, aminoglycoside antibiotics and cancer chemotherapy
can lead to both necrosis and apoptosis, ultimately leading to
deafness. JNK inhibition using the D-JNK-1 inhibitor peptide
provided otoprotective benefit in organ cultures of neonatal
mouse cochlea and in adult guinea pigs exposed to acoustic
trauma [73,74], suggesting JNK/SAPK inhibitors may be
important therapeutic targets for the prevention of cochlear
hair cell loss and deafness.
1.8. Neural tube birth defects
Concurrent loss of JNK1 and JNK2 in the JNK1−/−/JNK2−/−
double knockout results in defective neural tube development
manifested primarily as exencephaly [11,13]. The neurotube
defect is not seen in either JNK−/− or JNK2−/− animals
indicating a compensatory function in neural tube development
for the two JNK/SAPKs. Exencephaly in the JNK1/2 double
knockout embryos was due to enhanced apoptosis in the
forebrain and decreased apoptosis in the hindbrain [11].
Further examination of the JNK1−/− and JNK2−/− mice
demonstrated that the anterior commissure axons are absent in
JNK1 but not JNK2 knockout animals [12]. This is due to a
diminished microtubule-associated protein (MAP) 1 and 2
phosphorylation, where MAP1 and MAP2 are preferential
JNK1 substrates relative to JNK2 [12]. Phosphorylated
MAP1 and MAP2 promote microtubule polymerization. Thus,
loss of their phosphorylation causes shortening of neuronal
microtubules.
1.9. JNK/SAPK signaling pathway in cancer
The most insightful evidence for a role of JNK/SAPK
signaling modules in cancer has come from the identification of
MKK4 as a putative tumor suppressor [75–79]. MKK4 is a
MKK capable of phosphorylating both JNKs and p38 MAPKs.
This distinguishes MKK4 from MKK7 which has only been
shown to phosphorylate JNKs and not p38 MAPKs. Genetic
inactivation of the MKK4 gene on chromosome 17 p has been
reported for several different tumor types including a subset of
breast, biliary and pancreatic carcinomas [75,76]. In addition, inovarian and prostatic carcinomas epigenetic loss of MKK4
expression has been shown to be correlated with metastasis
[77–79]. More recently, studies with SKOV3ip.1 cells expres-
sing kinase-inactive MKK4 showed suppression of experi-
mental metastasis in nude mice [80]. In this study,
overexpression of MKK6 (p38 pathway) but not MKK7 (JNK
pathway) suppressed the SKOV3 cell growth in nude mice. The
results were interpreted that the p38 pathway and not the JNK
pathway, was the critical MAPK for the tumor suppressor
activity of MKK4. Additional models using MKK4 and MKK6
deficient cells will be required to substantiate this interpretation.
In a mouse model, JNK1 deficiency has been shown to
significantly decrease susceptibility to diethylnitrosamine-
induced hepatocarcinogenesis [81]. JNK1−/− but not JNK2−/−
mice were shown to have decreased expression of cyclin D and
VEGF, diminished hepatocyte proliferation and reduced tumor
neovascularization. The findings suggest that JNK1 inhibition
may be useful for therapeutic intervention and chemoprevention
of hepatocellular carcinoma.
Several studies suggest JNK can promote tumor cell growth
and therefore, is a useful anti-tumor target [82–85]. Furthermore,
JNK inhibitors block the induction of DNA repair genes in cells
treated withDNA damaging drugs [86]. However, JNK signaling
has also been shown to be critical for inducing apoptosis in
response to chemotherapeutic drugs [87]. Thus, JNKs have
opposing roles in promoting proliferation and transformation and
inducing apopotosis [88]. It seems that the effectiveness of JNK
inhibitors in treating human cancers may be very context
dependent for the specific tumor and cell origin [88].
1.10. JNK/SAPK signaling in chronic inflammatory diseases
JNK/SAPKs appear to have a significant role in chronic
inflammatory diseases involving the expression of specific
proteases and cytokines [89,90]. For example, JNK signaling
appears to be involved in the expression of metalloproteases,
which contributes to joint destruction in rheumatoid arthritis
[91]. JNKs also appear to contribute to the stimulation of TNFα
expression, a major pro-inflammatory cytokine in rheumatoid
arthritis. JNK inhibitors such as SP600125 and JNK1 deficiency
(JNK1−/− mice) suppressed metalloproteinase expression and
protected mice from joint damage in rheumatoid arthritis animal
models [91]. JNK2 deficiency (JNK2−/−) also suppressed
matrix degradation in joints, but did not significantly decrease
inflammation [92].
Atherosclerosis is a second chronic inflammatory disease
that appears to involve JNK/SAPK signaling [93,94]. Using the
ApoE−/− mouse model for atherosclerosis, it was shown that
deficiency of JNK2 (ApoE−/−/JNK2−/−) animals developed less
atherosclerosis than control ApoE−/− animals. JNK1 deficiency
did not reduce the level of atherosclerosis. JNK inhibitors were
also able to reduce the level of atherosclerosis. The mechanism
appears to be JNK2-dependent phosphorylation of the modified
lipid-binding and internalizing scavenger A receptor (SR-A)
that promotes uptake of lipids in macrophages contributing to
foam cell formation. The findings suggest specific JNK2
inhibitors may decrease atherogenesis.
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A therapeutic benefit may be the inhibition of JNKs in
metabolic regulation [95–97]. Obesity-induced insulin resis-
tance and diabetes are now worldwide disorders and a growing
health crisis. Insulin activation of its receptor stimulates the
receptors tyrosine kinase activity. Insulin Receptor Substrate 1
(IRS1) is phosphorylated on tyrosines by the insulin receptor.
The tyrosine phosphorylated IRS1 functions as a complex
scaffolding protein recruiting numerous signaling proteins in
the control of insulin signaling and metabolic regulation. The
JNKs phosphorylate IRS1 at S307 that results in reduced insulin
receptor catalyzed phosphorylation of IRS1 [98]. JNKs are
activated by high fat diet and obesity, in part due to elevated
levels of TNFα and IL-1 [95,97]. JNK1−/− mice and JIP1−/−
mice have improved insulin sensitivity that correlates with
reduced S307 phosphorylation [95,99]. JNK2−/− mice are
similar to wild type mice in their response to a high fat diet.
JIP1, is a scaffolding protein for JNK signaling, and interest-
ingly, a JIP1 gene mutation has been found in patients with a
form of type II diabetes [100]. Consistent with these findings, a
cell permeable JNK inhibitory peptide was shown to maintain
insulin sensitivity in the obese mouse model [42]. These
findings indicate JNK1 may be an important target in the
treatment of obesity and type II diabetes.
2. Conclusions
JNK/SAPKs are clearly involved in ischemia-induced cell
death and reperfusion injury in several different tissues and the
control of insulin sensitivity in metabolic regulation. There are
many other suggestions in the literature that link JNK/SAPK
signaling to additional human diseases such as type I diabetes,
osteosarcoma, ataxia and immune system dysfunction. JNKs
probably play a role in chronic inflammation, airway hyperre-
sponsiveness and protease-directed tissue remodeling. It is
likely that selective JNK1, JNK2 and JNK3 inhibitors will be
needed for specificity and lack of toxicity. It may also be useful
to develop specific MKKK inhibitors to selectively block JNK
activation in response to different upstream inputs [19].
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